Anemia of Chronic Kidney Disease
Conditions
Keywords
erythropoiesis-stimulating agent
Brief summary
An observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis.
Detailed description
Erythropoiesis-stimulating agent (ESA) has been commonly used to manage patients with end-stage renal disease receiving dialysis. The effects of ESA, however, are unclear. This study compares the result of erythropoiesis-stimulating agent (ESA) versus supportive care for chronic kidney disease patients receiving palliative care. The investigators design a retrospective observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis. The primary objective is to assess whether ESA can reduce the transfusion burden and hospitalization.
Interventions
DRUGErythropoiesis-Stimulating Agent
erythropoiesis-stimulating agent: Mircera or Darbepoietin
Sponsors
Chinese University of Hong Kong
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients aged 18 years and older, who opted for ESA treatment during palliative renal care for \> 360 days between January 1, 2014 and December 31, 2016
Exclusion criteria
* patients who had dialysis or kidney transplant treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of red cell transfusion | one year |
| days of hospitalisation | one year |
Countries
Hong Kong
Outcome results
None listed